公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2011 | Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells | Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; CHIH-HUNG HSU ; PEI-JER CHEN ; ANN-LII CHENG | Journal of Pharmacology and Experimental Therapeutics | 260 | 254 | |
2012 | Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity | Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 72 | 70 | |
2018 | Corrigendum to “Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity” (Eur. J. Med. Chem. (2012) 55 (220–227)(S0223523412004497)(10.1016/j.ejmech.2012.07.023)) | Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 1 | 1 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 1 | 1 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 0 | 1 | |
2014 | Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma | Tai W.-T.; Shiau C.-W.; PEI-JER CHEN ; Chu P.-Y.; HSIANG-PO HUANG ; Liu C.-Y.; Huang J.-W.; Chen K.-F. | Hepatology | 63 | 59 | |
2016 | Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis | Su J.-C.; Mar A.-C.; Wu S.-H.; Tai W.-T.; Chu P.-Y.; Wu C.-Y.; Tseng L.-M.; Lee T.-C.; Chen K.-F.; Liu C.-Y.; HAO-CHIEH CHIU ; Shiau C.-W. | Scientific Reports | 44 | 34 | |
2012 | Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3 | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Liu C.-Y.; Ko C.-H.; Lin M.-W.; PEI-JER CHEN ; Chen K.-F. | Molecular Cancer Therapeutics | 112 | 108 | |
2012 | Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3 | Chen K.-F.; Chen H.-L.; Liu C.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN ; ANN-LII CHENG | Biochemical Pharmacology | 40 | 35 | |
2012 | Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells | Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN ; ANN-LII CHENG | Biochemical Pharmacology | 50 | 50 | |
2013 | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells | Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; ANN-LII CHENG ; PEI-JER CHEN ; Chen K.-F. | Cell Death and Disease | 159 | 159 | |
2013 | SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells | CHEN-TI WANG ; Lin C.-S.; Shiau C.-W.; Chu P.-Y.; Hsiao C.-C.; Chiang Y.-L.; Tai W.-T.; Chen K.-F. | Journal of Orthopaedic Research | 9 | 6 | |
2014 | SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model | Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN ; Chen K.-F. | Molecular Cancer Therapeutics | 7 | 6 | |
2014 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer | Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN ; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Journal of Thoracic Oncology | 11 | 11 | |
2011 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; HSIANG-PO HUANG ; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 146 | 140 | |
2013 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody | Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN ; ANN-LII CHENG | British Journal of Pharmacology | 16 | 13 | |
2011 | Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf | Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG ; PEI-JER CHEN ; Shiau C.-W. | European Journal of Medicinal Chemistry | 32 | 29 | |
2010 | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3 | Chen K.-F.; Tai W.-T.; TSUNG-HAO LIU ; HSIANG-PO HUANG ; Lin Y.-C.; Shiau C.-W.; Li P.-K.; PEI-JER CHEN ; ANN-LII CHENG | Clinical Cancer Research | 147 | 145 | |
2014 | STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma | Tai W.-T.; Chu P.-Y.; Shiau C.-W.; Chen Y.-L.; Li Y.-S.; Hung M.-H.; Chen L.-J.; PEI-LUNG CHEN ; Su J.-C.; Lin P.-Y.; Yu H.-C.; Chen K.-F. | Clinical Cancer Research | 79 | 72 | |
2012 | Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists | Su J.-C.; Chen K.-F.; Chen W.-L.; Liu C.-Y.; Huang J.-W.; Tai W.-T.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 20 | 19 |